Emerging Biological Therapies on the Horizon for β-Thalassemia

Download this slideset for an expert-curated overview of emerging biological therapies for β-thalassemia, including review of the latest clinical data leading to the recent approval of the erythroid maturation agent luspatercept for transfusion-dependent disease.
Maria Domenica Cappellini, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.12 MB
Released: December 6, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Celgene Corporation

Related Content

Data from phase I GRAVITAS-119 on addition of itacitinib to calcineurin-based GVHD prophylaxis from ASH 2020, as reported by Clinical Care Options (CCO)

Released: December 18, 2020

CCO commentary from Stacy Croteau, MD, on the latest evidence from ASH 2020 on hemophilia management that is poised to impact clinical practice

Stacy Croteau Headshot Stacy E. Croteau, MD, MMS Released: December 18, 2020

Preliminary efficacy and safety from the phase I/II study of baricitinib for refractory cGVHD from ASH 2020, reported by Clinical Care Options (CCO)

Released: December 17, 2020

Phase I/II CLIMB THAL-111 and CLIMB SCD-121 studies of CTX001 for TDT and severe SCD from ASH 2020, reported by Clinical Care Options (CCO)

Released: December 16, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue